Prostatitis: acute bacterial, chronic, and CPPS — the AU GP approach

Prostatitis affects approximately 5% of Australian men in their lifetime, yet it is one of the most frequently misdiagnosed and mistreated conditions in general practice. The word “prostatitis” actually describes four distinct entities with very different causes, investigations, and treatments — and managing them all as infections leads directly to the antibiotic-cycling pattern that leaves men consulting multiple practitioners for months without improvement.

A. Core clinical — the AU general-practice framework

The NIH four-category classification

The 1999 NIH consensus (Krieger, JAMA) is the foundation for clinical thinking, dividing prostatitis into four categories:

Category I — Acute bacterial prostatitis. Rare but high-acuity. The patient is febrile, systemically unwell, with severe perineal, suprapubic, or low back pain, dysuria, and an exquisitely tender boggy prostate on rectal examination. Do not vigorously massage the prostate — bacteraemia risk is real. Send urine microscopy, culture and sensitivity, blood cultures if febrile, FBC, CRP, and renal function. Treat per eTG Antibiotic guidance: outpatient ciprofloxacin 500 mg twice daily or trimethoprim 300 mg daily for 14–28 days if clinically stable; inpatient IV gentamicin plus amoxicillin if septic. Arrange follow-up urine culture one week after completing antibiotics and defer PSA at least four to six weeks post-symptoms.

Category II — Chronic bacterial prostatitis. Defined by recurrent urinary tract infections caused by the same organism relapsing from a prostatic biofilm focus, with symptoms present for at least three months. Uropathogens include E. coli (~75%), Klebsiella, Pseudomonas, and Enterococcus. Treatment requires six weeks of ciprofloxacin — only fluoroquinolones, trimethoprim-sulfamethoxazole, and doxycycline reliably penetrate non-inflamed prostatic tissue. An alpha-blocker (tamsulosin 400 mcg daily) addresses voiding lower urinary tract symptoms alongside antibiotics. Men under 35 or who have sex with men require an STI assessment before assuming enteric organisms per the Australian STI Management Guidelines.

Category III — Chronic prostatitis / chronic pelvic pain syndrome (CPPS). This accounts for approximately 90% of all prostatitis presentations (EAU Urological Infections 2024) and no infection is detectable. The hallmark symptom is pelvic or perineal pain lasting three months or longer, particularly post-ejaculatory pain, which is highly characteristic. Pain may radiate to the penis tip, testes, inner thighs, or low back. Voiding lower urinary tract symptoms, sexual dysfunction, and significant mood impact are common. Category III is further subdivided into IIIa (inflammatory — white blood cells in expressed prostatic secretion or post-massage urine) and IIIb (non-inflammatory — sterile without WBC). This distinction guides the antibiotic decision on first presentation.

Category IV — Asymptomatic inflammatory prostatitis. An incidental finding on PSA workup, infertility investigation, or prostate biopsy. No treatment is generally indicated unless contributing to infertility or confounding cancer surveillance.

Taking the history

The RACGP recommends a biopsychosocial history that covers the six UPOINT domains (Shoskes, Urology 2009), as this directly guides individualised treatment:

• Urinary: storage symptoms (urgency, frequency, nocturia) versus voiding symptoms (hesitancy, weak stream, incomplete emptying)
• Psychosocial: depression, anxiety, catastrophising, impact on work, relationships, and quality of life
• Organ-specific: pelvic pressure, ejaculatory pain, pain at rest versus triggered, haematospermia
• Infection: prior acute episodes, response to antibiotics, STI risk
• Neurological: burning, shooting, or electric quality — suggests neuropathic central sensitisation
• Pelvic floor tenderness: worse with sitting or cycling, sacral or coccygeal referral, trigger-point-type pain

Also record: prior antibiotic courses (agent, duration, response), recent urological instrumentation or prostate biopsy, and occupational factors (prolonged sedentary work, vibrating machinery).

Examination

Rectal examination is essential. In Category I, palpate gently — firm massage risks bacteraemia. In Category III, examine both the prostate and the lateral pelvic floor muscles: approximately 50% of men with CPPS have palpable trigger points in the levator ani or obturator internus, often more tender than the prostate itself, per Anderson (J Urol, 2011). An external genitalia examination excludes epididymo-orchitis and urethritis.

Investigations

• All categories: urine microscopy, culture and sensitivity (MCS) — essential for classification and antibiotic selection
• Category I: blood cultures if febrile or septic; FBC, CRP, renal function; transrectal ultrasound only if no clinical improvement at 48–72 hours (to exclude prostatic abscess)
• Category II: pre- and post-massage two-glass urine test distinguishes Cat II (growth in post-massage specimen) from Cat III (sterile throughout) — this is the practical general practice equivalent of the Meares-Stamey four-glass test
• Category III: NIH Chronic Prostatitis Symptom Index (NIH-CPSI) at baseline quantifies symptom burden and tracks treatment response; post-void residual ultrasound if voiding symptoms are prominent
• PSA: defer at least four to six weeks after symptoms settle — transient elevation during inflammation is universal and leads to unnecessary cancer concern
• STI NAAT (urine): chlamydia and gonorrhoea PCR in men under 35, men who have sex with men, or anyone with urethral discharge, per Australian STI Management Guidelines

B. The evidence for UPOINT — and against empirical antibiotics in CPPS

The landmark evidence against empirical antibiotics in CPPS came from two randomised trials. The CPPSAR trial (Nickel, JAMA 2003) found ciprofloxacin was no better than placebo for CPPS. Alexander et al (Ann Intern Med, 2004) confirmed that neither ciprofloxacin nor tamsulosin alone improved outcomes in men with established CPPS.

The UPOINT phenotype framework, developed by Shoskes (Urology, 2009) and endorsed by both the AUA CP/CPPS 2022 guideline and the EAU Urological Infections 2024, matches treatment to each patient’s specific symptom combination rather than applying a single agent universally. Validated treatment by domain:

• U (Urinary): Alpha-blocker (tamsulosin 400 mcg daily, silodosin) — three-to-six month trial for storage or voiding-dominant symptoms
• P (Psychosocial): Cognitive behavioural therapy or acceptance and commitment therapy via a GP Mental Health Care Plan (Medicare items 2715/2717); addresses catastrophising, depression, and anxiety — all common and under-treated in CPPS
• O (Organ-specific): NSAIDs for inflammatory pain (short courses); phytotherapy — quercetin and pollen extract (cernilton) each have positive small randomised trials; regular ejaculation to reduce prostatic congestion
• I (Infection): A single four-to-six week antibiotic course (ciprofloxacin or doxycycline) in a treatment-naive patient with WBC-positive expressed prostatic secretion or post-massage urine. Repeat courses without microbiological evidence cause harm without benefit and drive resistance per ASID Antimicrobial Stewardship Guidelines
• N (Neurological): Amitriptyline 10–25 mg at night, titrating over four to six weeks; or a gabapentinoid (pregabalin or gabapentin — both PBS Authority for neuropathic pain and SafeScript-monitored) for the neuropathic pain phenotype
• T (Tenderness): Pelvic floor physiotherapy with biofeedback and trigger-point release is the single highest-value intervention for CPPS per Anderson (J Urol, 2011) — superior to any pharmacological intervention in that trial

C. The antibiotic stewardship problem

The most common error in CPPS management is repeated empirical antibiotic courses. Many men present having received three or more courses of ciprofloxacin without sustained benefit. This pattern is both ineffective and harmful.

The TGA has issued a Boxed Warning for ciprofloxacin covering tendinopathy and tendon rupture, aortic aneurysm and dissection, peripheral neuropathy, dysglycaemia, and mental health effects including psychosis and depression. Prescribing ciprofloxacin requires explicit informed consent and documentation of the clinical indication. CPPS without microbiological evidence of infection is not an appropriate indication for repeat courses.

Practical non-pharmacological strategies that carry no resistance risk and can be initiated at first presentation: warm sitz baths (10–15 minutes twice to three times daily), caffeine reduction, a four-week trial of eliminating bladder-irritant foods (alcohol, spicy foods, acidic fruits, carbonated drinks), and cycling saddle modification with regular standing breaks. Pelvic floor down-training exercises — notably not Kegel strengthening exercises, which worsen hypertonia — are valuable under physiotherapy guidance.

D. Australian operations

Medicare items relevant to prostatitis management:

• Standard GP attendances — items 3, 23, 36, 44
• GP Chronic Condition Management Plan (GPCCMP) item 965 / review item 967 — Category II and III prostatitis both qualify as chronic conditions; enables allied health referrals for pelvic floor physiotherapy (item 10960, five sessions per year aggregate across allied health)
• Mental Health Care Plan item 2715 / review 2717 — CBT or ACT for depression, anxiety, or chronic pain catastrophising in CPPS
• Urine MCS (item 69300), FBC (item 65070), CRP, PSA (item 66655)
• STI NAAT urine — chlamydia/gonorrhoea PCR (items 69317/69319) in at-risk men

Prescribing:

Ciprofloxacin for acute or chronic bacterial prostatitis is PBS Authority Streamlined — document indication and discuss the Boxed Warning explicitly. Trimethoprim and doxycycline are PBS general schedule alternatives. Alpha-blockers (tamsulosin, silodosin) are PBS Authority Streamlined for lower urinary tract symptoms. Gabapentinoids for neuropathic pain require PBS Authority and SafeScript monitoring — document indication and a risk-benefit assessment at every prescription.

Accessing pelvic floor physiotherapy:

The Australian Physiotherapy Association maintains a directory searchable by location and specialty for pelvic-health physiotherapists trained in male pelvic floor conditions. The five-session Medicare CDM annual cap is inadequate for CPPS — most patients need eight to twelve sessions. Private health fund extras and out-of-pocket supplement are often needed. Advise patients that improvement is typically gradual over three to six months; outcome expectations set at first consultation reduce attrition.

E. Special populations

Men under 35 or men who have sex with men: Always test for STI organisms — Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium — before committing to an enteric-organism treatment course. Urethral discharge, recent new partner, or unprotected anal sex are important triggers. The Australian STI Management Guidelines provide the AU-specific management framework.

Older men: Differentiate CPPS from benign prostatic hyperplasia — BPH presents predominantly with voiding lower urinary tract symptoms without the characteristic pain pattern of CPPS. A DRE nodule, rising PSA, or significant weight loss requires separate evaluation for prostate cancer.

Men with suspected abscess: Persistent fever and sepsis despite 48–72 hours of appropriate IV antibiotics should prompt transrectal ultrasound or MRI prostate to exclude a prostatic abscess requiring drainage by urology.

Men with significant mental health impact: The quality of life burden in CPPS is comparable in validated instruments to active Crohn disease or ischaemic heart disease. Suicidality risk in chronic disabling pelvic pain is real and deserves active screening and a safety plan — see the published resources on suicidality assessment and safety planning.

When to escalate

Refer to the emergency department or arrange same-day urgent contact for:

• Sepsis, rigors, haemodynamic instability, urinary retention (suprapubic catheter is preferred in acute bacterial prostatitis — urethral catheterisation is traumatic on the inflamed prostate)
• Suspected prostatic abscess — persistent fever after 48–72 hours of appropriate antibiotics

Refer to urology:

• Recurrent urinary tract infections in any male — same week
• Category II prostatitis that has not responded to a complete six-week course
• DRE abnormality (firm nodule) or PSA that remains elevated on a four-to-six week deferred test
• Category III CPPS with minimal response after three to six months of multimodal UPOINT management

Refer to a pelvic pain multidisciplinary team or pain medicine specialist for refractory CPPS causing significant functional disability.

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Therapeutic Guidelines, AMH, RACGP resources, USANZ, the EAU 2024 Urological Infections guideline, and AUA CP/CPPS 2022 — and major CPPS trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about specific investigations and treatment are made with your own GP and treating clinicians.

For Australian consumer-friendly information: HealthDirect — Prostatitis, Healthy Male (Andrology Australia), Continence Foundation of Australia, and Australian Physiotherapy Association — pelvic health physiotherapist finder.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Antibiotic: Prostatitis
2. Australian Medicines Handbook (AMH)
3. RACGP — prostatitis clinical resources
4. USANZ — Chronic pelvic pain in men
5. EAU Urological Infections Guideline 2024 (Bonkat et al.)
6. AUA — CP/CPPS Clinical Guideline 2022
7. Krieger JN et al. — NIH consensus classification, JAMA 1999
8. Shoskes DA et al. — UPOINT phenotyping framework, Urology 2009
9. Nickel JC et al. — Ciprofloxacin for CPPS (CPPSAR), JAMA 2003
10. Alexander RB et al. — Tamsulosin + ciprofloxacin for CPPS, Ann Intern Med 2004
11. Anderson RU et al. — Pelvic floor physical therapy for CPPS, J Urol 2011
12. TGA — Quinolone / fluoroquinolone safety advisory
13. Australian STI Management Guidelines
14. ASID Antimicrobial Stewardship Guidelines
15. HealthDirect — Prostatitis
16. Healthy Male (Andrology Australia)
17. Continence Foundation of Australia
18. Australian Physiotherapy Association — find a pelvic health physiotherapist